Full-length human glutaminase in complex with an allosteric inhibitor.
DeLaBarre, B., Gross, S., Fang, C., Gao, Y., Jha, A., Jiang, F., Song J, J., Wei, W., Hurov, J.B.(2011) Biochemistry 50: 10764-10770
- PubMed: 22049910 
- DOI: https://doi.org/10.1021/bi201613d
- Primary Citation of Related Structures:  
3UNW, 3UO9 - PubMed Abstract: 
Glutaminase (GLS1/2) catalyzes the conversion of L-glutamine to L-glutamate and ammonia. The level of a splice variant of GLS1 (GAC) is elevated in certain cancers, and GAC is specifically inhibited by bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES). We report here the first full-length crystal structure of GAC in the presence and absence of BPTES molecules. Two BPTES molecules bind at an interface region of the GAC tetramer in a manner that appears to lock the GAC tetramer into a nonproductive conformation. The importance of these loops with regard to overall enzymatic activity of the tetramer was revealed by a series of GAC point mutants designed to create a BPTES resistant GAC.
Organizational Affiliation: 
Agios Pharmaceuticals, Cambridge, Massachusetts 02139-4169, United States. byron.delabarre@agios.com